Novel risk score for patients undergoing Impella-assisted high-risk percutaneous coronary intervention.

Saved in:
Bibliographic Details
Title: Novel risk score for patients undergoing Impella-assisted high-risk percutaneous coronary intervention.
Authors: Lemor A; Department of Cardiology, University of Mississippi Medical Center, Jackson, MS, USA., Shah T; Division of Cardiovascular Medicine, Penn Medicine: University of Pennsylvania Health System, Philadelphia, PA, USA; Division of Cardiology, Yale School of Medicine, New Haven, CT, USA., Thompson JB; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA., Protty MB; Systems Immunity University Research Institute, Cardiff University, Cardiff, UK., Mamas MA; National Institute for Health Research School for Primary Care Research, Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Keele Cardiovascular Research Group, Centre for Prognosis Research, Keele University, Keele, UK; Department of Cardiology, Royal Stoke University Hospital, Stoke-on-Trent, UK., Kinnaird T; Department of Cardiology, University Hospital of Wales, Cardiff, UK., Bharadwaj AS; Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA., Truesdell AG; Virginia Heart / Inova Schar Heart and Vascular, Falls Church, VA, USA., Schonning MJ; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA., Zhang Y; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA., Hussain Y; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Veterans Affairs Connecticut Healthcare System, West Haven, CA, USA., Falah B; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA., Cohen DJ; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA; Department of Cardiology, St. Francis Hospital, Roslyn, NY, USA., Redfors B; Clinical Trials Center, Cardiovascular Research Foundation, NY, New York, USA; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA; Department of Molecular and Clinical Medicine, Gothenburg University, Gothenburg, Sweden; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden., Baron SJ; Massachusetts General Hospital, Boston, MA, USA; Baim Institute for Clinical Research, Boston, MA, USA., Witzke CF; Department of Medicine, Jefferson Einstein Hospital, Philadelphia, PA, USA; Department of Cardiology, Jefferson Einstein Hospital, Philadelphia, PA, USA., Dixon SR; Department of Cardiovascular Medicine, William Beaumont University Hospital, Royal Oak, MI, USA., Basir MB; Center for Structural Heart Disease, Division of Cardiology, Henry Ford Health System, Detroit, MI, USA., Lansky AJ; Division of Cardiology, Yale School of Medicine, New Haven, CT, USA; Barts Heart Centre, London and Queen Mary University of London, London, United Kingdom., O'Neill WW; Center for Structural Heart Disease, Division of Cardiology, Henry Ford Health System, Detroit, MI, USA. Electronic address: woneill1@hfhs.org.
Source: Cardiovascular revascularization medicine : including molecular interventions [Cardiovasc Revasc Med] 2025 Dec; Vol. 81, pp. 86-94. Date of Electronic Publication: 2025 May 30.
Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101238551 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0938 (Electronic) Linking ISSN: 18780938 NLM ISO Abbreviation: Cardiovasc Revasc Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1878-0938
DOI:10.1016/j.carrev.2025.05.031